Rapidol S 200 mg meke kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

rapidol s 200 mg meke kapsule

pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - ibuprofen - kapsula, meka - 200 mg - urbroj: jedna kapsula sadrži 200 mg ibuprofena

Rapidol S 400 mg meke kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

rapidol s 400 mg meke kapsule

pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - ibuprofen - kapsula, meka - 400 mg - urbroj: jedna kapsula sadrži 400 mg ibuprofena

Aldara Europska Unija - hrvatski - EMA (European Medicines Agency)

aldara

viatris healthcare limited - imikimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotici i kemoterapeutici za dermatološku uporabu - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Zyclara Europska Unija - hrvatski - EMA (European Medicines Agency)

zyclara

viatris healthcare limited - imikimod - keratosis; keratosis, actinic - antibiotici i kemoterapeutici za dermatološku uporabu - zyclara indicirana je za topikalno liječenje klinički tipične, ne-očigledni, sobe-hipertrofična, vidljiv ili opipljiv aktinička keratoza cijelo lice ili proćelav vlasišta u odraslih imunokompetentnih osoba kada su druge mogućnosti topikalna liječenje kontraindicirana ili manje prikladno.

Ontozry Europska Unija - hrvatski - EMA (European Medicines Agency)

ontozry

angelini pharma s.p.a - cenobamate - epilepsija - antiepileptici sredstva, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.